

Published bi-monthly by:



806328 Sideroad 25
Meaford, Ontario
N4L 1W7
Canada

Phone: 519-578-9897
www.multi-med.com

Current Oncology is indexed/covered in MEDLINE, PubMed, EMBASE, SCOPUS, CrossRef, DOAJ (Directory of Open Access Journals), Google Scholar, EMCare, EBSCOhost.com Research Databases, Science Citation Index Expanded (SciSearch), and Journal Citation Reports/Science Edition. Following publication in *Current Oncology*, the full text of each article is available immediately and archived in PubMed Central (PMC).

Peer Review Policy: All manuscripts are initially reviewed by the editorial staff, and if appropriate, will be assigned to a section editor. If the paper is judged to be suitable for possible publication, it will be sent to two or more external reviewers using our database of experts. All articles undergo this process with the following exceptions, which do not undergo our standard review process:

- **Letters to the Editor, Commentaries and Editorials** are based on the decision of the Editor, who may ask experts on the merit of their contents.
- **Practices Guidelines/Consensus Statements** - Special considerations may be made in this case as they are typically authored by experts in the field. The authors of the manuscript are asked to sign a form stating they have approved the manuscript and it is acceptable for publication. If they choose not to sign this, they must provide a list of five potential reviewers to review the manuscript, and the article will go through our standard peer review process. The Editors reserve the right to choose all reviewers and may not necessarily select reviewers from the list provided.
- **Meeting Reports** – based on the decision of the Editor.
- **Special Articles** – depending on the format and content, special articles may be solely based on the decision of the Editor, or undergo our standard review process.

Canada Post Publications Mail
Account Number: 40020215

Printed in Canada

ISSN (Print): 1198-0052
ISSN (Online): 1718-7729

CURRENT ONCOLOGY

A Canadian Cancer Research Journal

VOLUME 27, SUPPLEMENT 3, NOVEMBER 2020

EDITORIAL

S136 The evolving treatment landscape of hepatocellular carcinoma: more choices, more responsibility

S. Gill MD MPH MBA

REVIEW ARTICLES

S138 Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve

S.Z. Frager MD and J.M. Schwartz MD

S144 Current locoregional therapies and treatment strategies in hepatocellular carcinoma

L. Cardarelli-Leite MD, A. Hadjivassiliou MBBS BSc, D. Klass MBChB MD, J. Chung MD, S.G.F. Ho MD, H.J. Lim MD PhD, P.T.W. Kim MD MSc, A. Mujoomdar MD, and D.M. Liu MD

S152 Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions

A. Weinmann MD MBA and P.R. Galle MD PhD

S165 Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease

S. Perera MD PhD, D. Kelly MB BCh BAO MRCP, and G.M. O'Kane MB BCh BAO MD MRCP

S173 Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond

C.P. Amaro MD and V.C. Tam BSc(Hon) MD

This supplement was made possible through the support of Eisai Co. Ltd., Merck Canada Inc., Sirtex Medical Limited and Hoffmann–La Roche Limited. The opinions expressed in this material do not necessarily reflect the views of our supporters. *Current Oncology* is thankful for their support of this project and for their ongoing commitment to research and education in cancer.